RxDoctor Payments Data

Barbara Schechter, DO

Cardiovascular Disease · Eatontown, NJNPI 1427440932

Payments from drug & device makers

$7,508in general payments, 2019–2025

Across 79 payments — averaging $95.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Edwards Lifesciences$673
  • Boston Scientific$418
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$280
  • AstraZeneca$266
  • Novartis$260
  • plus $619 from 11 others

What the payments were for

  • Travel & lodging$3,08641%
  • Food & beverage$4,11855%
  • Education$3044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,508 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$449,141
Medicare patients
1,498
Services billed
4,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$349,868
VyndamaxTafamidis12$267,746
XareltoRivaroxaban84$85,889
Repatha SureclickEvolocumab76$66,647
EntrestoSacubitril/Valsartan48$65,034
FarxigaDapagliflozin Propanediol34$40,313
Praluent PenAlirocumab50$31,090
MultaqDronedarone Hcl28$25,912
JardianceEmpagliflozin13$13,930
Rosuvastatin Calcium913$12,802
NexletolBempedoic Acid15$10,404
Dabigatran EtexilateDabigatran Etexilate Mesylate21$7,794
Metoprolol Succinate442$7,217
Valsartan109$5,810
Icosapent Ethyl15$4,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$45$617,615290 claims
NovartisEntresto$260$65,03448 claims
AstraZenecaFarxiga$266$40,31334 claims
Esperion Therapeutics, Inc.Nexletol$16$10,40415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →